06 MacNeil COVID 508
Document text
Evidence to Recommendations (partial) for 2025 –2026 COVID -19 Vaccination Coronavirus and Other Respiratory Viruses Division June 25, 2025National Center for Immunization and Respiratory Diseases 1 Evidence to Recommendations ( EtR) Framework EtR Domain Question(s) Public Health Problem •Is the problem of public health importance? Benefits and Harms•How substantial are the desirable anticipated effects? •How substantial are the undesirable anticipated effects? •Do the desirable effects outweigh the undesirable effects? Values•Does the target population feel the desirable effects are large relative to the undesirable effects? •Is there important variability in how patients value the outcome? Acceptability •Is the intervention acceptable to key stakeholders? Feasibility •Is the intervention feasible to implement? Resource Use •Is the intervention a reasonable and efficient allocation of resources? Equity •What would be the impact of the intervention on health equity? •May 29th work group call -Public Health Problem domain of the Evidence to Recommendations ( EtR) Framework was presented •June 5th work group call -Benefits and Harms domain of the EtR was presented •June 12th planned work group call -Additional EtR domains were planned to be presented -Final work group polling not completed because call was not convenedWork Group Interpretations 3 Summary Public Health Problem •Burden from COVID -19 has been trending down year over year since 2021, but substantial morbidity and mortality continues to occur. •Higher rates of COVID -19 hospitalization and deaths occur in the oldest and youngest age groups. -Highest rates in adults ages ≥65 years and infants ages <6 months •Children ages <2 years have the highest morbidity and mortality of all pediatric ages, but deaths due to COVID -19 can occur at any age. -Maternal vaccination is the best protection against COVID -19 for pregnant women and infants less than 6 months of age (who are too young to be vaccinated). •2024 –2025 COVID -19 vaccination is effective in preventing hospitalizations and critical outcomes from COVID -19 in adults. -Data from prior vaccine formulations show that vaccine effectiveness has been similar across age groups. •COVID -19 vaccines have been continuously monitored through robust safety surveillance •Safety surveillance identified and characterized the risk of myocarditis and pericarditis after mRNA COVID -19 vaccination. -No other risks confirmed in the current U.S. -licensed vaccines except those seen with other vaccines (e.g., local and systemic reactions, allergic reactions). •Pregnant women are at increased risk of severe disease and adverse pregnancy outcomes from COVID -19. •Maternal vaccination has been shown to protect infants <6 months of age from severe outcomes of COVID -19.Summary Benefits and Harms Thank you to all the CDC and external collaborators who contributed to these presentations.